

In the Claims

Please cancel claim 1.

Please add the following new claims:

Sul B1
--24. A method for treating an autoimmune disorder in a patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from said patient;
- b) treating said cells with a regulatory composition to generate regulatory T cells; and
- c) reintroducing said regulatory T cells to said patient to suppress an aberrant immune response.

*A2
cont'd*
25. A method according to claim 24 wherein said aberrant immune response is a cell-mediated autoimmune disease selected from the group consisting of Hashimoto's disease, polymyositis, disease inflammatory bowel disease, multiple sclerosis, diabetes mellitus, rheumatoid arthritis, and scleroderma.

26. A method for treating an autoimmune disorder in a patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from said patient;
- b) treating said cells with a regulatory composition to induce said cells to produce immunosuppressive levels of TGF- β ; and
- c) reintroducing said cells to said patient to suppress aberrant immune responses.

27. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises TGF- β

28. A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises TGF- β

29. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises TGF- β .

30. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises TGF- β and IL-2.

31. A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises TGF- β and IL-2.

32. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises TGF- β and IL-2.

33. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD2.

34. A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD2.

35. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD2.

36. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD2.

37. A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD2.

38. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD2.

39. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD3.

40. A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD3.

41. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and CD8+ T cells and said regulatory composition comprises a mixture of TGF- β and anti-CD3.

42. A method according to claim 24 or 26 wherein said PBMCs comprise CD4+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD3.

43. A method according to claim 24 or 26 wherein said PBMCs comprise CD8+ T cells and said regulatory composition comprises a mixture of TGF- β , IL-2 and anti-CD3.